Point Therapeutics, Inc. Announces Phase 2 Poster Presentations at Upcoming Scientific Meetings

   NSCLC Poster Accepted for Presentation at AACR-NCI-EORTC
Conference and Single Agent Melanoma Poster Accepted for Presentation
at iSBTC Annual Meeting

   Point Therapeutics, Inc. (NASDAQ: POTP) announced that it has had
posters accepted for presentation at two upcoming scientific meetings.
The company has evaluated additional data from its Phase 2 trials of
talabostat in combination with docetaxel in metastatic non-small cell
lung cancer (NSCLC) and talabostat as a single agent in metastatic
melanoma and intends to present results at these meetings.
   In the NSCLC Phase 2 trial, an analysis of all patients enrolled
in the trial showed an increase in median progression free survival
over the previously reported interim results of 4.0 months. These
results further support the company's recent initiation of its Phase 3
program in metastatic NSCLC because progression free survival is the
primary endpoint in the Phase 3 program. The additional NSCLC Phase 2
trial results will be presented in detail at an upcoming poster
presentation at the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics on Wednesday, November 16,
2005.
   The company is also conducting a Phase 2 program, evaluating
talabostat in metastatic melanoma. This program consists of two
trials--a single agent talabostat trial and a combination trial of
talabostat with cisplatin. In the single agent trial, it has been
determined that there are no additional responders beyond those
previously reported. However, the median survival results are
generally consistent with those of the currently approved chemotherapy
standard of care. In addition, talabostat has demonstrated a more
favorable adverse event profile in this study and is orally
administered while the current standard of care is administered
intravenously. The company expects that median survival will be an
important clinical endpoint required for registration. The additional
metastatic melanoma Phase 2 trial results will be presented in detail
at an upcoming poster presentation at the International Society for
the Biological Therapy of Cancer Annual Meeting on Saturday, November
12, 2005.
   "We are pleased with the results from our clinical development
programs, including that our three complete responders--two from our
lung cancer trial and one from our single agent melanoma
trial--continue to be complete responders," said Don Kiepert,
President and CEO of Point Therapeutics, Inc. "In addition to
implementing our Phase 3 non-small cell lung cancer program, we
continue to evaluate our Phase 2 metastatic melanoma program and
expect to announce by year-end whether or not we believe the results
merit pursuing a Phase 3 program. It is, however, unlikely that the
company would initiate a Phase 3 metastatic melanoma trial without a
partner. We look forward to presenting updated results at the upcoming
scientific meetings," concluded Kiepert.

   About Point:

   Point is a Boston-based biopharmaceutical company developing a
family of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
it lead product candidate, talabostat, in a Phase 3 trial in NSCLC.
Point is also studying talabostat in several Phase 2 trials, including
as a single agent in metastatic melanoma, in combination with
cisplatin in metastatic melanoma, in combination with rituximab in
advanced chronic lymphocytic leukemia, and in combination with
gemcitabine in metastatic pancreatic cancer. In addition, Point's
portfolio includes two other DPP inhibitors in preclinical
development--PT-630 for type 2 diabetes, and PT-510 as a vaccine
adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-Q for the quarter ended June
30, 2005 and from time to time in Point's periodic and other reports
filed with the Securities and Exchange Commission.